Wang, H., Ashton, R., Hensel, J. A., Lee, J. H., Khattar, V., Wang, Y., . . . Ponnazhagan, S. (2020). RANKL-targeted combination therapy with osteoprotegerin variant devoid of TRAIL binding exerts biphasic effects on skeletal remodeling and antitumor immunity. Mol Cancer Ther.

Wang, Hong, Reading Ashton, Jonathan A. Hensel, Joo Hyoung Lee, Vinayak Khattar, Yong Wang, Jessy S. Deshane, e Selvarangan Ponnazhagan. "RANKL-targeted Combination Therapy With Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects On Skeletal Remodeling and Antitumor Immunity." Mol Cancer Ther 2020.

Wang, Hong, et al. "RANKL-targeted Combination Therapy With Osteoprotegerin Variant Devoid of TRAIL Binding Exerts Biphasic Effects On Skeletal Remodeling and Antitumor Immunity." Mol Cancer Ther 2020.